Hemodialysis patient

Infections in hemodialysis patients may be related to the choice of membranes, the complement-activating membranes being more deleterious. 

Oxidative stress and inflammation are elevated in hemodialysis patients, which, at least partly, might be initiated by intravenous iron administration. Thus, Tovbin et al. [377] showed that the administration of iron saccharide to hemodialysis patients increased the blood level of oxidized proteins. Similarly, an increase in the levels of free ( nontransferrin-bound or labile ) iron has been shown in the plasma of hemodialysis patients [378] including patients after intravenous iron saccharate infusion [379]. 

Infusion Iron sucrose may be also administered by infusion (into the dialysis line for hemodialysis patients). This may reduce the risk of hypotensive episodes. The content of each vial must be diluted exclusively in a maximum of 100 ml of 0.9% NaCI, immediately prior to infusion. Infuse the solution at a rate of 100 mg of iron over a period of 15 minutes or more. Discard unused diluted solution. 

Hemodialysis patients Median dose is 75 units/kg 3 times/week (range, 12.5 to 525 units/kg 3 times/week). 

In hemodialysis patients or in case of acute renal failure (Ccr less than 15 mL/min or serum creatinine more than 6 mg/dL), avoid or stop infusion of lepirudin. Consider additional IV bolus doses of 0.1 mg/kg every other day only if the aPTT ratio falls below the lower therapeutic limit of 1.5. ... 

Elderly (77 years of age and older) - 5 mg once daily as recommended. Renal/Hepatic function impairment - In patients 12 years of age and older with decreased renal function (Ccr 11 to 31 mL/min), hemodialysis patients (Ccr less than 7 mL/min), and in hepatically impaired patients, 5 mg once daily is recommended. 

Renally impaired patients Augmentin XR is contraindicated in severely impaired patients with a Ccr of less than 30 mL/min and in hemodialysis patients. 

Hemodialysis patients - In patients undergoing hemodialysis 2 or 3 times weekly, a single 400 mg dose of ceftibuten capsules or a single dose of 9 mg/kg (maximum of 400 mg) oral suspension may be given at the end of each hemodialysis session. 

Renal function impairment Plasma clearance of meropenem correlates with Ccr. In moderate renal dysfunction (Ccr 30 to 80 mL/min), mean half-life has been prolonged to 1.93 to 3.36 hours. In patients with greater dysfunction (Ccr 2 to 30 mg/min), mean half-life has been further prolonged to 3.82 to 5.73 hours. Patients undergoing hemodialysis (patients with end-stage renal disease) had mean... 

Hemodialysis patients Do not prescribe valganciclovir to patients receiving hemodialysis. 

Hemodialysis patients The recommended dose is 20 mg every 24 hours (60 kg or more) or 15 mg every 24 hours (less than 60 kg) administered after the completion of hemodialysis and at the same time of day on nondialysis days. 

Hemodialysis patients if dosing on day of dialysis, administer after dialysis. P.1127... 

Dosing in hemodialysis patients If tinidazole is administered on a day when dialysis is performed, administer an additional dose of tinidazole equivalent to one half the recommended dose after the end of the hemodialysis. 

Hopfer SM, Fay WP, Sunderman FW Jr. 1989. Serum nickel concentrations in hemodialysis patients with environmental exposure. Arm Clin Lab Sci 19 161-167. 

Pharyngitis or tonsillitis PO 300 mg ql2h for 5-10 days or 600 mg q24h for 10 days. Uncomplicated skin or skin-structure infections PO 300 mg q 12h for 10 days Dosage in renal impairment For patients with creatinine clearance less than 30 ml/min, dosage is 300 mg/day as single daily dose. For hemodialysis patients, dosage is 300 mg or 7 mg/kg/dose every other day. 

Dosage in hemodialysis patients For adults with herpes zoster, give 250 mg after each dialysis treatment for adults with genital herpes, give 125 mg after each dialysis treatment. 

Dosage in hemodialysis patients IV 2.25gq8h with additional dose of 0.75g after each dialysis session. 

Lee, J., Richburg, J.H., Younkin, S.C. Boekelheide, K. (1997) The Fas system is a key regulator of germ cell apoptosis in the testes. Endocrinology, 128, 2081-2088 Lewis, D.F.V Lake, B.G. (1993) Interaction of some peroxisome prolrferators with the mouse liver peroxisome proliferator-activated receptor (PPAR) a molecular modelling and quantitative stracture-activity relationship (QSAR) study. Xenobiotica, 23, 79-96 Lewis, L.M., Flechtner, T.W., Kerkay, J., Pearson, K.H. Nakamoto, S. (1978) Bis(2-ethyl-hexyl) phthalate concentrations in the serum of hemodialysis patients. Clin. Chem., 24, 741-746... 

Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid. Kidney Int 62 2246-2249... 

In 40 ambulatory hemodialysis patients, 25 of whom were taking pioglitazone and 15 rosiglitazone, there were no increases in intravascular volume, anemia, edema, or chronic heart failure in a retrospective study (61). It may be that dialysis obviates any increase in intravascular volume. The use of these drugs during dialysis seems to be safe, although there were reductions in systolic and diastolic blood pressures. 

Hottelart C, Achard JM, Moriniere P, Zoghbi F, Dieval J, Fournier A. Heparin-induced hyperkalemia in chronic hemodialysis patients comparison of low molecular weight and unfractionated heparin. Artif Organs... 

Fanti P, Sawaya PB, Custer LJ, Franke AA. 1999. Serum levels and metabolic clearance of the isoflavones genistein and daidzein in hemodialysis patients. J Am Soc Nephrol... 

Kimmel PL, Weihs K, Peterson RA. Survival in hemodialysis patients The role of depression. J Am Soc Nephrol 1993 3 12-27. 

Huang TL, Lee CT. Serum albumin and ferritin levels in chronic hemodialysis patients with or without major depression. International Congress of Biological Psychiatry, February 9-13, 2004. Sydney, abstract 88. 

When there is inadequate elimination of aluminum from the body, as in nondialyzed uremic patients, increased aluminum concentrations are detected in serum, bone tissue, liver, spleen, brain, and skeletal muscle (Alfrey et al. 1980 Arieff et al. 1979). In hemodialysis patients exposed by infusion to large amounts of aluminum over long periods of time (with inadequate removal of aluminum by the kidneys and dialysis machines), increased aluminum concentrations are observed mostly in the spleen, followed by the liver and skeletal system (Alfrey 1980 Alfrey et al. 1980). 

Huang J-Y, Huang C-C, Lim PS, et al. 1992. Effect of body iron stores on serum aluminum level in hemodialysis patients. Nephron 61 158-162. 

There is now good evidence for a role of presynaptic neuropeptide Y receptors in disease states. As to the cardiovascular system, plasma neuropeptide Y levels are slightly increased in hypertensive patients and to a greater extent in cardiac failure (Morris 2004). An increase in neuropeptide Y levels is even an important prognostic marker for cardiovascular death in hemodialysis patients (Odar-Cederlof et al. 

---